D. Boral Capital Reiterates Buy Rating for AVITA Medical (NASDAQ:RCEL)

AVITA Medical (NASDAQ:RCEL)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a research note issued to investors on Friday,Benzinga reports. They currently have a $25.00 target price on the stock. D. Boral Capital’s price target would indicate a potential upside of 136.52% from the company’s current price.

RCEL has been the subject of a number of other reports. Lake Street Capital lowered their price target on AVITA Medical from $20.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 target price on shares of AVITA Medical in a report on Tuesday, December 24th. Finally, Piper Sandler reiterated a “neutral” rating and set a $12.00 price target (up from $9.00) on shares of AVITA Medical in a research note on Friday, November 8th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, AVITA Medical presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

AVITA Medical Stock Up 20.4 %

Shares of AVITA Medical stock opened at $10.57 on Friday. The company has a quick ratio of 3.37, a current ratio of 3.73 and a debt-to-equity ratio of 3.48. AVITA Medical has a 52-week low of $7.51 and a 52-week high of $18.93. The company has a market capitalization of $277.12 million, a P/E ratio of -4.74 and a beta of 1.55. The company has a 50 day moving average of $10.69 and a 200 day moving average of $10.59.

AVITA Medical (NASDAQ:RCEL) last released its quarterly earnings data on Thursday, February 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.14). AVITA Medical had a negative return on equity of 194.69% and a negative net margin of 95.47%. The firm had revenue of $18.41 million for the quarter, compared to analysts’ expectations of $18.40 million. As a group, research analysts forecast that AVITA Medical will post -2.38 EPS for the current fiscal year.

Institutional Trading of AVITA Medical

A number of large investors have recently bought and sold shares of the business. Huntington National Bank acquired a new stake in shares of AVITA Medical during the third quarter worth about $32,000. FMR LLC lifted its position in AVITA Medical by 126.9% during the 3rd quarter. FMR LLC now owns 4,248 shares of the company’s stock worth $46,000 after acquiring an additional 2,376 shares during the period. Russell Investments Group Ltd. grew its stake in shares of AVITA Medical by 48.0% in the 4th quarter. Russell Investments Group Ltd. now owns 7,164 shares of the company’s stock valued at $92,000 after purchasing an additional 2,324 shares during the last quarter. Quest Partners LLC increased its holdings in shares of AVITA Medical by 269.4% in the third quarter. Quest Partners LLC now owns 7,520 shares of the company’s stock valued at $81,000 after purchasing an additional 5,484 shares during the period. Finally, AlphaQuest LLC raised its stake in shares of AVITA Medical by 24.7% during the fourth quarter. AlphaQuest LLC now owns 9,378 shares of the company’s stock worth $120,000 after purchasing an additional 1,858 shares during the last quarter. Institutional investors and hedge funds own 27.66% of the company’s stock.

About AVITA Medical

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.